Modera Wealth Management LLC Sells 3,416 Shares of Elevance Health, Inc. $ELV

Modera Wealth Management LLC cut its holdings in Elevance Health, Inc. (NYSE:ELV) by 9.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,319 shares of the company’s stock after selling 3,416 shares during the period. Modera Wealth Management LLC’s holdings in Elevance Health were worth $10,979,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Physician Wealth Advisors Inc. boosted its holdings in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after purchasing an additional 63 shares during the period. Activest Wealth Management boosted its holdings in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares during the period. Rossby Financial LCC boosted its holdings in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after purchasing an additional 44 shares during the period. Motco boosted its holdings in Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after purchasing an additional 77 shares during the period. Finally, True Wealth Design LLC boosted its holdings in Elevance Health by 431.8% in the 3rd quarter. True Wealth Design LLC now owns 117 shares of the company’s stock valued at $38,000 after purchasing an additional 95 shares during the period. 89.24% of the stock is owned by institutional investors.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: CMS finalized a larger-than-expected Medicare Advantage/Part D rate increase (~2.48% average), and officials noted additional upside from risk-adjustment changes (~+2.5% effective boost), which materially raises expected 2027 revenue for government-program-focused insurers like Elevance. Elevance Health Stock Soars After 2.48% Medicare Rate Increase
• Positive Sentiment: Coverage across sites highlights the CMS decision as a clear tailwind for health insurers; several outlets point to ELV among top beneficiaries, supporting upside to margins and earnings versus prior street expectations. Health insurance stocks are soaring on a Medicare update. Here’s what you need to know.
• Positive Sentiment: Analyst commentary and trade pieces (Seeking Alpha, 247WallSt) characterize the new Medicare payment rate as a gift for Elevance, arguing it improves near-term earnings power and valuation after recent underperformance. Medicare Rates Up – What This Really Means For Elevance
• Positive Sentiment: Market analysts/providers that track managed care updated views and at least one major bank (BofA) raised its price target on Elevance, supporting the rally and signaling improved sentiment among institutional investors. BofA Updates Managed Care Outlook, Raises Elevance Health (ELV) Price Target
• Neutral Sentiment: Commentary pieces remind investors that Elevance still faces structural headwinds (membership declines, higher benefit expense ratios, muted guidance), so while CMS action helps, execution and membership trends remain key near-term drivers. Is It Time To Reassess Elevance Health (ELV) After A 27% One-Year Share Price Slide
• Neutral Sentiment: Elevance leadership changes are under coverage; analysts question whether the shuffle will refocus the company on government-program execution—an important but uncertain medium-term factor. Will Elevance Health’s (ELV) Leadership Shuffle Refocus Its Core Advantage In Government Programs?
• Neutral Sentiment: Pre-earnings commentary previews upcoming results and highlights what to watch (membership trends, benefit expense, FY guidance), providing context that near-term guidance will still drive forward moves after the policy-driven lift. Elevance Health earnings preview: What to expect
• Positive Sentiment: Investment write-ups arguing ELV is deeply discounted and technically poised for a rebound added to buying interest on the policy news, reinforcing the bullish case for long-term EPS recovery. Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good

Elevance Health Stock Performance

Elevance Health stock opened at $311.22 on Wednesday. The firm’s fifty day moving average price is $312.98 and its 200-day moving average price is $332.28. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a market cap of $68.36 billion, a P/E ratio of 12.39, a price-to-earnings-growth ratio of 1.65 and a beta of 0.49. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the company posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities research analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were given a dividend of $1.72 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date was Tuesday, March 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.2%. Elevance Health’s dividend payout ratio is 27.39%.

Analyst Ratings Changes

Several brokerages have commented on ELV. Jefferies Financial Group cut their price target on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a report on Friday, January 30th. JPMorgan Chase & Co. raised their price target on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Guggenheim cut their price target on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a report on Thursday, January 29th. Finally, Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Twelve analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and an average target price of $387.40.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.